Skip to main content
Fig. 1 | BMC Medical Research Methodology

Fig. 1

From: Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis

Fig. 1

Evidence Network Comparing Biologics for Moderate to Severe Rheumatoid Arthritis, ACR50 Response. Treatment nodes are sized to proportionally reflect the numbers of patients randomized to each intervention, while the line thickness of edges joining nodes are asized to propotionally reflect the numbers of studies informing each comparison. Legend: ABA = abatacept; ADA = adalimumab; BAR_4 = 4 mg baricitinib; CERTO = certolizumab pegol; csDMARD = conventional synthetic disease-modifying anti-rheumatic drug; ETN = etanercept; GOL = golimumab; INF = infliximab; IV = intravenous; MTX = methotrexate; RIT = rituximab; SAR_200 = 200 mg sarilumab; SC = subcutaneous; SSZ = sulfasalazine; STD = standard dose; TOC_4 = tocilizumab 4 mg/kg; TOC_8 = 8 mg/kg tocilizumab; TOF = tofacitinib

Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us